Studies in animals ro

If the electronic databases do not capture all of that information, then with respect to a High Value Account, the Reporting Financial Institution must also review the current customer master file and, to the extent not contained in the current customer master file, the following documents associated with the account and obtained by the Reporting Financial Institution within the last five years for any of the indicia described in subparagraph B(2)

A Reporting Financial Institution is not required to perform the paper record search described in subparagraph C(2) to the extent the Reporting Financial Institution's electronically searchable information includes the following

the most recent account opening contract or documentation

any power of attorney or signature authority forms currently in effect and

If the paper search fails to establish an indicium and the attempt to obtain the self certification or Documentary Evidence is not successful, the Reporting Financial Institution must report the account to the Competent Authority of its Member State or San Marino, as the context requires, as an undocumented account.

The following enhanced review procedures apply with respect to High Value Accounts.

Electronic record search.

If none of the indicia listed in subparagraph B(2) are discovered in the electronic search, then no further action is required until there is a change in circumstances that results in one or more indicia being associated with the account, or the account becomes a High Value Account.

a self certification from the Account Holder of the jurisdiction(s) of residence (being a Member State, Andorra or other jurisdictions) of such Account Holder that does not include such Reportable Jurisdiction

There are no adequate data from the use of APTIVUS in pregnant women.

There are no adequate data from the use of oseltamivir in pregnant women.

There are no adequate data from the use of entecavir in pregnant women.

There are no adequate data from the use of BYETTA in pregnant women.

There are no adequate data from the use of CHAMPIX in pregnant women.

There are no adequate data from the use of sirolimus in pregnant women.

There are no adequate data on the use of reteplase in pregnant women.

There are no adequate data from the use of Zonegran in pregnant women.

There are no adequate data from the use of Eucreas in pregnant women.

There are no adequate data from the use of Icandra in pregnant women.

There are no adequate data from the use of fentanyl in pregnant women.

There are no adequate data from the use of ziconotide in pregnant women.

5 There are no adequate data from the use of Zomarist in pregnant women.

18 There are no adequate data from the use of Zomarist in pregnant women.

the endometrial safety of Activelle 0.5mg estradiol 0.1mg NETA product is sufficiently supported

There are no adequate data from the use of bivalirudin in pregnant women.

There are no adequate data from the use of vildagliptin in pregnant women.

Pregnancy There are no adequate data on the use of imatinib in pregnant women.

There are no adequate data from the use of pregabalin in pregnant women.

There are no adequate data from the use of Pradaxa in pregnant women.

There are no adequate data from the use of Pradaxa in pregnant women.

There are no adequate data from the use of tacrolimus ointment in pregnant women.

There are no adequate data from the use of desirudin in pregnant women.

Pregnancy There are no adequate data from the use of dasatinib in pregnant women.

There are no data on the use of ceftriaxone in pregnant women.

There are no adequate data from the use of gabapentin in pregnant women.

With sufficient data, we do have methods to identify the likely causes of an economic phenomenon.

There are no adequate data from the use of agalsidase beta in pregnant women.

There are no adequate data from the use of lapatinib in pregnant women.

There are no adequate data on the use of zoledronic acid in pregnant women.

There are no adequate data from the use of rosiglitazone in pregnant women.

There are no adequate data from the use of filgrastim in pregnant women.

There are no adequate data from the use of cysteamine bitartrate in pregnant women.

There are no adequate data from the use of fentanyl in pregnant women.

There are no adequate data from the use of Fareston in pregnant women.